Effective biomodulation by leucovorin of high-dose infusion fluorouracil given as a weekly 24-hour infusion: Results of a randomized trial in patients with advanced colorectal cancer

Journal of Clinical Oncology

Volumn 16, Issue 2, 1998, Pages 418-426

  Köhne, Claus Henning ^a   Schoffski P ^a   Wilke, H ^a   Kaufer C ^a   Andreesen, R ^a   Ohl, U ^a   Klaasen, U ^a   Westerhausen, M ^a   Hiddemann, W ^a   Schott, G ^a   Harstick, A ^a   Bade, J ^a   Horster, A ^a   Schubert, U ^a   Hecker, H ^a   Dorken B ^a   Schmoll, H J ^a  

^a Section of Pathology   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

ALPHA2B INTERFERON; FLUOROURACIL; FOLINIC ACID;

ADULT; ADVANCED CANCER; AGED; ARTICLE; CANCER CHEMOTHERAPY; CANCER GRADING; CLINICAL TRIAL; COLORECTAL CANCER; CONTINUOUS INFUSION; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DIARRHEA; DOSE RESPONSE; DRUG EFFICACY; DRUG MEGADOSE; FEMALE; HUMAN; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; REMISSION; SUBCUTANEOUS DRUG ADMINISTRATION; TREATMENT OUTCOME;

EID: 0345403552     PISSN: 0732183X     EISSN: None     Source Type: Journal    
DOI: 10.1200/JCO.1998.16.2.418     Document Type: Article

References (40)

1. Grem JL, McAtee N, Murphy RF, et al: A pilot study of interferon alfa-2a in combination with fluorouracil plus high-dose leucovorin in metastatic gastroinestinal carcinoma. J Clin Oncol 9:1811-1820, 1991
2. Lokich JJ, Ahlgren JD, Gullo JJ, et al: A prospective randomized comparison of continuous infusion fluorouracil with a conventional bolus schedule in metastatic colorectal carcinoma: A Mid-Atlantic Oncology Program Study. J Clin Oncol 7:425-432, 1989
3. Hansen RM, Ryan L, Anderson T, et al: Phase III study of bolus versus infusion fluorouracil with or without cisplatin in advanced colorectal cancer. J Natl Cancer Inst 88:668-674, 1996
4. Weinerman B, Shah A, Fields A, et al: Systemic infusion versus bolus chemotherapy with 5-fluorouracil in measurable metastatic colorectal cancer. Am J Clin Oncol 15:518-523, 1992
5. Haas NB, Hines JB, Hudes GR, et al: Phase I trial of 5-fluorouracil by 24-hour infusion weekly. Invest New Drugs 11:181-185, 1993
6. Ardalan B, Chua L, Tian EM, et al: A phase II study of weekly 24-hour infusion with high-dose fluorouracil with leucovorin in colorectal carcinoma. J Clin Oncol 9:625-630, 1991
7. Ardalan B, Sridhar KS, Benedetto P, et al: A phase I, II study of high-dose 5-fluorouracil and high-dose leucovorin with low-dose phosphonacetyl-L-aspartic acid in patients with advanced malignancies. Cancer 68:1242-1246, 1991
8. Rustum YM, Trave F, Zakrzewski SF, et al: Biochemical and pharmacologic basis for potentiation of 5-fluorouracil action by leucovorin. Natl Cancer Inst Monogr 5:165-170, 1987
9. Modulation of fluorouracil by leucovorin in patients with advanced colorectal cancer: Evidence in terms of response rate. Advanced Colorectal Cancer Meta-Analysis Project. J Clin Oncol 10:896-903, 1992
10. Chu E, Zinn S, Boarman D, et al: Interaction of gamma interferon and 5-fluorouracil in the H630 human colon carcinoma cell line. Cancer Res 50:5834-5840, 1990
11. Gewert DR, Moore G, Clemens MJ: Inhibition of cell division by interferons. The relationship between changes in utilization of thymidine for DNA synthesis and control of proliferation in Daudi cells. Biochem J 214:983-990, 1983
12. Wadler S, Schwartz EL: Antineoplastic activity of the combination of interferon and cytotoxic agents against experimental and human malignancies: A review. Cancer Res 50:3473-3486, 1990
13. Houghton JA, Adkins DA, Rahman A, et al: Interaction between 5-fluorouracil, [6RS] leucovorin, and recombinant human interferon α-2a in cultured colon adenocarcinoma cells. Cancer Commun 3:220-224, 1991
14. Schüller J, Czejka MJ, Schernthaner G, et al: Influence of interferon alfa-2b with or without folinic acid on pharmacokinetics of fluorouracil. Semin Oncol 19:93-97, 1992
15. Danhauser LL, Freimann JH, Gilchrist TL, et al: Phase I and plasma pharmacokinetic study of infusional fluorouracil combined with recombinant interferon alfa-2b in patients with advanced cancer. J Clin Oncol 11:751-761, 1993
16. Sparano JA, Wadler S, Diasio RB, et al: Phase I trial of low-dose, prolonged continuous infusion fluorouracil plus interferon-alfa: Evidence for enhanced fluorouracil toxicity without pharmacokinetic perturbation. J Clin Oncol 11:1609-1617, 1993
17. Wadler S, Schwartz EL, Goldman M, et al: Fluorouracil and recombinant alfa-2a-interferon: An active regimen against advanced colorectal carcinoma. J Clin Oncol 7:1769-1775, 1989
18. Köhne-Wömpner CH, Schmoll HJ, Harstrick A, et al: Chemotherapuetic strategies in metastatic colorectal cancer: An overview of current clinical trials. Semin Oncol 19:105-125, 1992
19. Köhne CH, Wilke H, Hecker H, et al: Interferon-alpha does not improve the antineoplastic efficacy of high-dose infusional 5-fluorouracil plus folinic acid in advanced colorectal cancer. First results of a randomized multicenter study by the Association of Medical Oncology of the German Cancer Society (AIO). Ann Oncol 6:461-466, 1995
20. Whitehead J: Interim analyses and stopping rules in cancer clinical trials. Br J Cancer 68:1179-1185, 1993
21. Kaplan EL, Meier P: Nonparametric estimation from incomplete observations. J Am Stat Assoc 457-481, 1958
22. Peto R, Pike MC, Armitage P, et al: Design and analysis of randomized clinical trials requiring prolonged observation of each patient. II. Analysis and examples. Br J Cancer 35:1-39, 1977
23. Marcus R, Peritz E, Gabriel KR: On closed testing procedures with special reference to ordered analysis of variance. Biometrika 63:655-660, 1976
24. Meta-analysis of randomized trials testing the biochemical modulation of fluorouracil by methotrexate in metastatic colorectal cancer. Advanced Colorectal Cancer Meta-Analysis Project. J Clin Oncol 12:960-969, 1994
25. Löffler TM, Weber FW, Hausamen TU: Double modulation of 5-Fluorouracil (FU) with leucovorin (LV) and interferon-alpha-2b in metastatic colorectal cancer: Results of a pilot study. Onkologie 14:25, 1991 (abstr, suppl)
26. Buroker TR, O'Connell MJ, Wieand HS, et al: Randomized comparison of two schedules of fluorouracil and leucovorin in the treatment of advanced colorectal cancer. J Clin Oncol 12:14-20, 1994
27. Hryniuk WM, Figueredo A, Goodyear M: Applications of dose intensity to problems in chemotherapy of breast and colorectal cancer. Semin Oncol 14:3-11, 1987 (suppl 4)
28. Cunningham D, Zalcberg JR, Rath U, et al: 'Tomudex' (ZD1694): Results of a randomised trial in advanced colorectal cancer demonstrate efficacy and reduced mucositis and leucopenia. The 'Tomudex' Colorectal Cancer Study Group. Eur J Cancer 31A:1945-1954, 1995
29. de Gramont A, Bosset JF, Milan C, et al: A randomized trial comparing monthly low-dose leucovorin/fluorouracil bolus with bi-monthly high-dose leucovorin/fluorouracil bolus plus continuous infusion for advanced colorectal cancer: A French intergroup study. J Clin Oncol 15:808-815, 1997
30. Köhne CH, Hiddeman W, Schüller J, et al: Failure of orally administered dipyridamole to enhance the antineoplastic activity of fluorouracil in combination with leucovorin in patients with advanced colorectal cancer: A prospective randomized trial. J Clin Oncol 13:1201-1208, 1995
31. Leichman CG, Fleming TR, Muggia FM, et al: Phase II study of fluorouracil and its modulation in advanced colorectal cancer: A Southwest Oncology Group study. J Clin Oncol 13:1303-1311, 1995
32. Hill M, Norman A, Cunningham D, et al: Impact of protracted venous infusion fluorouracil with or without interferon alfa-2b on tumor response, survival, and quality of life in advanced colorectal cancer. J Clin Oncol 13:2317-2323, 1995
33. Blijham G, Wagener T, Wils J, et al: Modulation of high-dose infusional fluorouracil by low-dose methotrexate in patients with advanced or metastatic colorectal cancer: Final results of a randomized European Organization for Research and Treatment of Cancer Study. J Clin Oncol 14:2266-2273, 1996
34. Weh HJ, Wilke HJ, Dierlamm J, et al: Weekly therapy with folinic acid (FA) and high-dose 5-fluorouracil (5-FU) 24-hour infusion in pretreated patients with metastatic colorectal carcinoma. A multicenter study by the Association of Medical Oncology of the German Cancer Society (AIO). Ann Oncol 5:233-237, 1994
35. O'Dwyer PJ, Ryan LM, Valone FH, et al: Phase III trial of biochemical modulation of 5-fluorouracil by IV or oral leucovorin or by interferon in advanced colorectal cancer: An ECOG/CALGB phase III trial. Proc Am Soc Clin Oncol 15:207, 1996 (abstr)
36. Greco FA, Figlin R, York M, et al: Phase III randomized study to compare interferon alfa-2a in combination with fluorouracil versus fluorouracil alone in patients with advanced colorectal cancer. J Clin Oncol 14:2674-2681, 1996
37. Kosmidis PA, Tsavaris N, Skarlos D, et al: Fluorouracil and leucovorin with or without interferon alfa-2b in advanced colorectal cancer: Analysis of a prospective randomized phase III trial. Hellenic Cooperative Oncology Group. J Clin Oncol 14:2682-2687, 1996
38. Seymour MT, Slevin ML, Kerr DJ, et al: Randomized trial assessing the addition of interferon α-2a to fluorouracil and leucovorin in advanced colorectal cancer. Colorectal Cancer Working Party of the United Kingdom Medical Research Council. J Clin Oncol 14:2280-2288, 1996
39. Hill M, Norman A, Cunningham D, et al: Royal Marsden phase III trial of fluorouracil with or without interferon alfa-2b in advanced colorectal cancer. J Clin Oncol 13:1297-1302, 1995
40. Dufour P, Husseini F, Dreyfus B, et al: 5-Fluorouracil versus 5-fluorouracil plus α-interferon as treatment of metastatic colorectal carcinoma: A randomized study. Ann Oncol 7:575-579, 1996